Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 23, 2020

Marijuana Impacts the Progression of HPV Related Head and Neck Squamous Cell Carcinoma

Author(s):

Conor Killmurray

Marijuana is often linked to fighting cancer and its effects, but in the case of head and neck squamous cell carcinoma, researchers found that it may increase the progression of the disease.

Cannabinoids may accelerate the growth of human papilloma virus (HPV)-related head and neck squamous cell carcinoma, according to a new study published in Clinical Cancer Research. Researchers identified that the molecular mechanism of tetrahydrocannabinol (THC), the ingredient that causes people to feel the euphoric “high” associated with marijuana use, activates the p38 mitogen-activated protein kinases (MAPK) pathway, which allows cancer cells to grow uncontrollably.

“I think it may change how we counsel patients, quite frankly,” said Dr. Joseph A. Califano III, in an interview with CURE® on the impact of this study for patients with HPV-related head and neck squamous cell carcinoma (HNSCC).

“The old association data people didn't pay much attention to, but these data are actually a little bit more definitive and have a real biological mechanism associated with why these compounds [impact] cancer,” he explained. “Once you see that, you start shifting towards counseling patients to avoid cannabinoids if they have this cancer.”

Califano, a professor, surgeon scientist, and vice chief of the Division of Otolaryngology in the Department of Surgery at UC San Diego School of Medicine, was one of the senior authors on the study that looked at patients with HPV-related HNSCC and the association of increased marijuana use to the progression of their cancer.

While a previous study in 2008 showed an association between HPV-related throat cancer and daily marijuana use, researchers in this study set out to find a biological reason for the interaction of cannabinoids and HPV-positive HNSCC. What they found was the cannabinoids’ activation of the p38 MAPK pathway in the bloodstream was stopping normal cell death from occurring, thus leading to cancer cells growing unchecked.

“It's a very classic cancer pathway,” Califano explained, “there are no MAPK inhibitors and no ways to treat modulate that particular pathway, both upstream and downstream.”

Furthermore, researchers cautioned that there needs to be further evaluation of cannabinoids used to fight cancer, but Califano wanted patients to understand that there is not a binary in the use of marijuana. Its use is not just good or just bad, as each patient and tumor type react differently.

“For this particular cancer, there's no question daily use is implicated as a risk factor,” Califano elaborated. “Daily users who are worried about this tumor type probably want to not use on a daily [basis]. That said, this tumor, head and neck is still on the rare side of cancers.”

Califano and the other researchers believe the next steps for this research are finding a way to block cannabinoids in this pathway, and potentially use the cannabinoid access to the pathway to help turn it off. They also want to investigate the CBD effects on this pathway as the research only focused on the THC effect on it.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of bald man.
Image of man with black hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Dr. Michael Moore
Dr. Michael Moore
Dr. Michael Moore
Related Content
Advertisement
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma: © stock.adobe.com.
April 24th 2025

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

Alex Biese
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
April 9th 2025

Breaking Down Treatment Options for Patients With Head and Neck Cancer

Alex Biese
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
Related Content
Advertisement
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma: © stock.adobe.com.
April 24th 2025

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

Alex Biese
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
April 9th 2025

Breaking Down Treatment Options for Patients With Head and Neck Cancer

Alex Biese
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.